

ASX Announcement

Notice under Section 708A(5)(e) of the Corporations Act

Perth, Australia; 11 September 2026: Regenerative medicine company Orthocell Limited (ASX: OCC, “Orthocell” or the “Company”) is pleased to advise that it has today issued 61,750 fully paid ordinary shares (“New Shares”) following the exercise of 61,750 unlisted options with an exercise price of \$0.36 and an expiry date of 19 April 2027.

The Company hereby gives notice under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (“**Act**”) of the issue of the New Shares. The Act restricts the on-sale of securities issued without disclosure unless the sale is exempt under section 708 or 708A of the Act. By the Company giving this notice (“**Notice**”), a sale of the New Shares will fall within the exemption in section 708A(5) of the Act and they will be able to be traded immediately.

For the purposes of section 708A(6) of the Act, the Company gives notice that:

- (a) the New Shares were issued without disclosure to investors under Part 6D.2 of the Act;
- (b) this Notice is being given under section 708A(5)(e) of the Act;
- (c) as at the date of this Notice the Company has complied with:
 - (i) the provisions of Chapter 2M of the Act, as they apply to the Company; and
 - (ii) sections 674 and 674A of the Act; and
- (d) as at the date of this Notice there is no information that is ‘excluded information’ within the meanings of sections 708(A)(7) and 708A(8) of the Act that is required to be set out in this notice.

Release authorised by:
Paul Anderson
Orthocell Ltd CEO and MD
Release authorised by:
Paul Anderson
Orthocell Ltd CEO and MD

For more information, please contact:

General enquiries

Paul Anderson
Orthocell Limited

Media enquiries

Haley Chartres
H^{ACK} Director

Investor enquiries

Shaun Duffy
VECTOR Advisors



About Orthocell Limited

ACN 118 897 135

Registered Office – Level 2, 161 Campus Drive, Murdoch University, Murdoch WA 6150 Australia

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell's portfolio of products include a platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for dental GBR applications, is cleared for use in the US, Australia, New Zealand, Singapore, UK, Europe, Canada and Brazil and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, recently gained clearance for use in the US. The Company has appointed a network of specialist US distributors and recorded initial sales. The Company's flagship nerve repair product is also approved in Australia, New Zealand and Singapore where it is distributed by Device Technologies Group. Other Remplir approvals include Thailand, Canada and Hong Kong. SmrtGraft™, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company's other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer and FDA engagement to confirm the path to the US market and prepare for partnering discussions.

For more information on Orthocell, please visit www.orthocell.com or follow us on Twitter @OrthocellLtd and LinkedIn www.linkedin.com/company/orthocell-ltd